Going it alone with the oral, once-daily factor Xa inhibitor betrixaban, for which Merck & Co. Inc. handed back rights in 2011, Portola Pharmaceuticals Inc. marches ahead, following a pre-specified futility analysis by the APEX phase III trial's monitoring board.